LEE'S PHARM (00950) surged over 21% in late trading, closing up 16.02% at HK$21 with trading volume reaching HK$31.96 million.

On the news front, LEE'S PHARM previously released its interim results showing the group achieved revenue of HK$695 million, representing a 5.5% year-over-year increase, primarily driven by robust sales performance across the group's product portfolio. Net profit attributable to shareholders for the first half of 2025 reached HK$67.185 million, up 7.5% year-over-year. This performance strengthens the sustainable growth trajectory established last year and reflects the group's continued consolidation of operational strength and financial discipline. Earnings per share stood at HK$0.1141.

Notably, LEE'S PHARM announced in late July that its subsidiary Zhaoke Oncology's marketing application for a new indication of the anti-PD-L1 monoclonal antibody socazolimab has received approval. According to LEE'S PHARM's public information, the newly approved indication is for first-line treatment of extensive-stage small cell lung cancer in combination with chemotherapy. This milestone marks the second approved indication for socazolimab injection, following its initial conditional approval for treating recurrent or metastatic cervical cancer.